Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial - Shimura Masahiko (JAPANESE JOURNAL OF OPHTHALMOLOGY, 2023)